Letter to the Editor Regarding the Article “Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma”
Restricted accessLetterFirst published online November, 2015
Letter to the Editor Regarding the Article “Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma”
WangLY, SmithAW, PalmerFL, TuttleRM, MahrousA, NixonIJ, PatelSG, GanlyI, FaginJA, BoucaiL. 2015. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid, 25:300–307.
2.
SchneiderR, SchneiderM, ReinersChr, SchneiderP. 2012. Effects of levothyroxine on bone mineral density, muscle force and bone turnover markers: a cohort study. J Clin Endocrin Metab, 297:3926–3934.
3.
RendlS, LapaC, BlümelC, BundschuhRA, SchneiderP. 2013. Decision making for osteoporotic treatment using FRAX or DVO risk algorithms in a clinical setting. J Musculoskelet Neuronal Interact, 13:339–345.
